Streetbeat News

Earnings

ESAB

ESAB reported Q1 2024 adjusted EPS of $1.20, surpassing the $1.10 estimate, and sales of $689.744M, exceeding the $664.869M estimate. This represents a 9.09% increase in EPS and a 0.84% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:33 am

UTHR

United Therapeutics (NASDAQ:UTHR) reported Q1 2024 GAAP EPS of $6.17, surpassing the $5.56 estimate, with a 10.97% beat. Sales reached $677.7M, exceeding the $623.966M estimate by 8.61%, marking a 33.70% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:32 am

WLKP

Westlake Chemical (NYSE:WLKP) reported Q1 2024 earnings of $0.42 per share, missing the consensus estimate of $0.43 by 2.33%. Sales were $284.673M, exceeding estimates by 1.31% but marking a 7.48% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:32 am

CVS

CVS shares are trading lower due to worse-than-expected Q1 earnings per share (EPS) and revenues.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:32 am

GTHX

G1 Therapeutics (NASDAQ:GTHX) reported Q1 2024 earnings with a GAAP EPS of $(0.20), meeting analyst estimates, and a 62.26% improvement from last year's $(0.53) per share. However, their sales of $14.476M fell short of the $15.259M estimate, a 5.13% miss, though it represents an 11.82% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:32 am

TECH

Bio-Techne (NASDAQ:TECH) reported Q3 adjusted earnings of $0.48 per share, surpassing the $0.45 estimate, and sales of $303.43M, exceeding the $292.19M estimate. This represents a 9.43% decrease in earnings and a 3.16% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:31 am

COR

Cencora has provided its adjusted EPS forecast for FY24, projecting a range of $13.30 to $13.50, which is around the current analyst estimate of $13.45.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:31 am

CVS

CVS Health reported Q1 2024 adjusted EPS of $1.31, missing the $1.69 estimate, and sales of $88.437B, missing the $89.209B estimate. This represents a 40.45% decrease in EPS and a 3.70% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:31 am

IDXX

IDEXX Laboratories (IDXX) reported Q1 2024 earnings of $2.81 per share, surpassing the $2.67 estimate, but sales of $964M missed the $966.13M forecast, marking a 7.09% year-over-year increase.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:31 am

COR

Cencora reported Q2 2024 adjusted EPS of $3.80, surpassing the $3.69 estimate. However, its sales of $68.400M fell short of the $70.653B estimate, missing by 99.90%.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 10:30 am